E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Adult Growth Hormone Deficiency (AGHD) |
deficit dell’ormone della crescita (GHD/AGHD) |
|
E.1.1.1 | Medical condition in easily understood language |
Lack of growth hormone in the body |
Mancanza di ormone della crescita nel corpo |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Hormonal diseases [C19] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10056438 |
E.1.2 | Term | Growth hormone deficiency |
E.1.2 | System Organ Class | 10014698 - Endocrine disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety of once-weekly lonapegsomatropin in adults with GHD previously treated in trial TCH-306. |
valutare la sicurezza della lonapegsomatropina una volta alla settimana negli adulti con deficit dell’ormone della crescita (GHD/AGHD) precedentemente trattati nello studio TCH-306. |
|
E.2.2 | Secondary objectives of the trial |
1. To evaluate the efficacy of once-weekly lonapegsomatropin in adults with GHD. 2. To evaluate the pharmacodynamics (PD) of once-weekly lonapegsomatropin in adults with GHD. 3. To evaluate the pharmacokinetics (PK) of once-weekly lonapegsomatropin in adults with GHD. |
1. Valutare l'efficacia di lonapegsomatropina una volta alla settimana negli adulti con GHD. 2. Per valutare la farmacodinamica (PD) di lonapegsomatropina una volta alla settimana negli adulti con GHD. 3. Valutare la farmacocinetica (PK) di lonapegsomatropina una volta alla settimana negli adulti con GHD. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Signing of the trial specific informed consent. 2. Completion of the treatment period and Visit 7 assessments of trial TCH-306, including collection and upload of Visit 7 DXA scan. 3. Fundoscopy at Visit 7 in trial TCH-306 without signs/symptoms of intracranial hypertension or diabetic retinopathy stage 2 / moderate or above. |
1. Firma del consenso informato specifico dello studio. 2. Completamento del periodo di trattamento e valutazione della visita 7 dello studio TCH-306, inclusa la raccolta e il caricamento della scansione DXA della visita 7. 3. Fundoscopy alla visita 7 nello studio TCH - 306 senza segni/sintomi di ipertensione intracranica o retinopatia diabetica fase 2 / moderata o superiore. |
|
E.4 | Principal exclusion criteria |
1. Diabetes mellitus if any of the following are met: a. Poorly controlled diabetes, defined as HbA1C higher than 7.5% according to central laboratory at Visit 6 in trial TCH-306 b. Use of diabetes mellitus drugs other than metformin and/or dipeptidyl peptidase-4 (DPP-4) inhibitors 2. Active malignant disease or history of malignancy. Exceptions are: a. Resection of in situ carcinoma of the cervix uteri b. Complete eradication of squamous cell or basal cell carcinoma of the skin 3. Known history of hypersensitivity and/or idiosyncrasy to the investigational product (somatropin or excipients) 4. Female who is pregnant, plans to become pregnant, or is breastfeeding 5. Female participant of childbearing potential (i.e., fertile, following menarche and until becoming post-menopausal unless permanently sterile) not willing throughout the trial to use contraceptives as required by local law or practice. Details included in Appendix 4/section 10.4 of this protocol 6. Male participant not willing throughout the trial to use contraceptives as required by local law or practice. Details included in Appendix 4/ section 10.4 of this protocol 7. Any disease or condition that, in the judgement of the investigator, may make the participant unlikely to comply with the requirements of the protocol or any condition that presents undue risk from the investigational product or trial procedures 8. eGFR <60 mL/min/1.73m² determined based on Modification of Diet in Renal Disease (MDRD) equation using serum creatinine from the central laboratory at screening 9. Hepatic transaminases (ie, AST or ALT) >3 times the upper limit of normal according to the central laboratory at screening |
1. Diabete mellito se si verifica una delle seguenti condizioni: a. Diabete scarsamente controllato, definito come HbA1c superiore al 7,5% secondo central laboratorio alla visita 6 nella prova TCH-306 b. Uso di farmaci per il diabete mellito diversi dalla metformina e / o dalla dipeptidil peptidasi-4 (DPP-4) inibitori 2. Malattia maligna attiva o storia di malignità. Le eccezioni sono: a. Resezione del carcinoma in situ della cervice uterina b. Completa eradicazione del carcinoma a cellule squamose o basali della pelle 3. Anamnesi nota di ipersensibilità e / o idiosincrasia al prodotto sperimentale (somatropina o eccipienti) 4. Donna che è incinta, sta pianificando una gravidanza o sta allattando 5. Partecipante femminile in età fertile (cioè fertile, dopo il menarca e fino a diventare post-menopausa a meno che non sia permanentemente sterile) non disposto durante la prova ad usare contraccettivi come richiesto dalla legge o dalla pratica locale. Dettagli inclusi nell'appendice 4 / sezione 10.4 del presente protocollo 6. Partecipante maschio non disposto durante la prova per usare i contraccettivi come richiesto dal locale legge o pratica. Dettagli inclusi nell'appendice 4 / sezione 10.4 del presente protocollo 7. Qualsiasi malattia o condizione che, a giudizio dello sperimentatore, possa rendere il partecipante è improbabile che rispetti i requisiti del protocollo o qualsiasi condizione che presenti indebite rischio derivante dal prodotto sperimentale o dalle procedure di sperimentazione 8. eGFR < 60 mL/min/1, 73m2 determinato in base alla modifica della dieta nell'equazione della malattia renale (MDRD) utilizzando la creatinina sierica del laboratorio centrale allo screening 9. Transaminasi epatiche (cioè, AST o ALT) > 3 volte il limite superiore del normale secondo il laboratorio centrale allo screening |
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Adverse events (AEs) • Laboratory values • Vital signs • Immunogenicity • 12-lead electrocardiogram (ECGs) • Fundoscopy |
* Eventi avversi (AE) * Valori di laboratorio * Segni vitali * Immunogenicità * elettrocardiogramma a 12 derivazioni (Ecg) * Fundoscopia |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
throughout the treatment period of 52 weeks |
durante il periodo di trattamento di 52 settimane |
|
E.5.2 | Secondary end point(s) |
Efficacy endpoints (as assessed by dual-X-rayabsorptiometry (DXA): • Trunk percent fat • Trunk fat mass • Total body lean mass
PD endpoints: • IGF-1 values and IGF-1 SDS
PK endpoints: • hGH, lonapegsomatropin, and mPEG values |
Endpoint di efficacia (valutati mediante assorbimetria a doppio raggio X (DXA): * Tronco per cento di grasso * Massa grassa del tronco * Massa magra totale del corpo
Endpoint PD: * IGF-1 valori e IGF-1 SDS
Endpoint PK: * hGH, lonapegsomatropin, e mPEG valori |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Efficacy endpoints At week 52 PD endpoints throughout the treatment period of 52 weeks PK endpoints from week 17 to week 52 |
Endpoint di efficacia alla settimana 52 Endpoint PD durante il periodo di trattamento di 52 settimane Endpoint PK dalla settimana 17 alla settimana 52 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
In aperto |
open-label extension trial |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 48 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Canada |
Israel |
Japan |
New Zealand |
United States |
France |
Poland |
Netherlands |
Romania |
Spain |
Germany |
Greece |
Italy |
Armenia |
Georgia |
Slovakia |
Turkey |
Ukraine |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
ultima visita dell'ultimo soggeto |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 30 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 1 |
E.8.9.2 | In all countries concerned by the trial days | 9 |